



dk/B
py
12.17.01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Art Unit:
)	
GRØFTE, Thørbjørn et al)	
)	
)	Washington, D.C.
)	
U.S. App. No.: 09/928,832)	
)	November 19, 2001
National Filing Date: 8/14,/2001))	
)	
For: TREATMENT OF ACUTE AND...)	Docket No.: GRØFTE=1A

PRELIMINARY AMENDMENT

Honorable Commissioner for Patents and Trademarks
Washington, D.C. 20231

Sir:

Prior to examination upon the merits, kindly amend
as follows:

IN THE CLAIMS

- B'
18. (Amended) Method of claim 1, wherein said pharmaceutically effective amount of IGF-1 is about 100 microgram per day per kilogram of treated individual.
19. (Amended) Method of claim 1, wherein the IGF-1 is recombinant IGF-1, or a variant thereof, produced by recombinant DNA technology.
20. (Amended) Method of claim 1, wherein said composition further comprises at least one IGF-1 binding protein (IGFBP) selected from the group consisting of IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5, and IGFBP-6, and variants thereof.

REMARKS

The above amendments to the claims are being made in order to eliminate any properly multiply dependent claims, for

the purpose of reducing the filing fee. Please enter this amendment prior to calculation of the filing fee in this case.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with Markings to Show Changes Made."

Favorable consideration and allowance are earnestly solicited.

Respectfully submitted,
BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant

By: _____
Iver P. Cooper
Registration No. 28,005

IPC:sfg
Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528
F:\,H\hoib\groftela\PTO\Preliminary Amendment.doc